At the Blog
On Monday, Hilary Allen explained how Silicon Valley Venture Capitalists turned “innovation” into a smokescreen for regulatory arbitrage—and how we underwrite this corrosive behavior by showering VCs with public subsidies.
On Tuesday, Amy Kapczynski concluded our series on market power in medicine by discussing some of the challenges facing programs like “CalRx” that seek to produce public medicines like insulin. The main barrier to public pharma, she argues, is not technical. Nor is it red tape. It’s the existence of significant private interests that stand in the way of such efforts at every step.
And on Thursday, Maryam Jamshidi argued that the recent US sanctions against Francesca Albanese—a human rights expert whose work threatens several major American corporations—exemplify the economic goals that are part and parcel of U.S. sanctions policy.
In LPE Land
In case you’ve been living under a rock, or perhaps traveling around Europe pretending to be Dickie Greenleaf, the Inaugural Association of Law and Political Economy Conference will be taking next February in Richmond. Proposals for paper panels, individual papers, and roundtables are due between Aug. 15 and Sept. 15. You can find more information on the ALPE website.
Cool CfP: The AALS Section on Employee Benefits and Executive Compensation is looking for LPE people interested in presenting at its main program, Trump 2.0’s Impact on Employee Benefits, this coming January in New Orleans. More details about the program can be found here, and the due date for submissions is Sept. 12.
Are you a mid-career scholar whose position in a certain proto-fascist state has become untenable and who would like to experience the mysteries of the Coriolis effect? The University of New South Wales in Sydney has twelve 1-2 year Green Fellowships available. Applications due August 10th.
At Techdirt, Karl Bode rightly observes that Trump 2.0 Support For Lina Khan Style Antitrust Reform Wound Up Being An Unsurprising Lie.
At Legal Form, Abby Cartus maps out the deeper contours of the Trump administration’s approach to data production and governance.
At Balls and Strikes, Steve Kennedy and Heather Atherton explain How Trump’s “Big, Beautiful Bill” Will Make Law School Unaffordable For People Who Are Not Already Rich.
On her Blog, Rebecca Spang discusses what’s really happening with state “legal tender” laws.
Over at the Regulatory Review, the great Lisa Heinzerling analyzes the EPA’s attempts to reinterpret the Clean Air Act.
Cool event alert: next week, the Roosevelt Institute will host a conversation on the legal complexities and economic constraints of the post-Dobbs landscape, featuring Kate Bahn and Rachel Rebouché.
